CN111643547A - Composition and preparation method thereof - Google Patents
Composition and preparation method thereof Download PDFInfo
- Publication number
- CN111643547A CN111643547A CN202010574137.3A CN202010574137A CN111643547A CN 111643547 A CN111643547 A CN 111643547A CN 202010574137 A CN202010574137 A CN 202010574137A CN 111643547 A CN111643547 A CN 111643547A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- weight
- herb
- lithospermum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 23
- 241001071917 Lithospermum Species 0.000 claims abstract description 15
- 240000003664 Maclura cochinchinensis Species 0.000 claims abstract description 15
- 241000915604 Scutellaria barbata Species 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 11
- 241000522190 Desmodium Species 0.000 claims abstract description 8
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 28
- 201000010260 leiomyoma Diseases 0.000 claims description 11
- 241000632227 Antenoron Species 0.000 claims description 9
- 241000130781 Arnebia Species 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 241001571764 Lysimachia christinae Species 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 239000000463 material Substances 0.000 abstract description 8
- 230000002411 adverse Effects 0.000 abstract description 2
- 238000009835 boiling Methods 0.000 abstract description 2
- 238000010025 steaming Methods 0.000 abstract description 2
- 241000207929 Scutellaria Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 230000002175 menstrual effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 4
- 201000007954 uterine fibroid Diseases 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 240000001659 Oldenlandia diffusa Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 244000286838 Eclipta prostrata Species 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 244000179560 Prunella vulgaris Species 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 235000008113 selfheal Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000097654 Cudrania tricuspidata Species 0.000 description 1
- 235000010918 Cudrania tricuspidata Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 235000007810 Eryngium campestre Nutrition 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000299507 Gossypium hirsutum Species 0.000 description 1
- 235000009432 Gossypium hirsutum Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 235000015912 Impatiens biflora Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000001549 Ipomoea eriocarpa Species 0.000 description 1
- 235000005146 Ipomoea eriocarpa Nutrition 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000612166 Lysimachia Species 0.000 description 1
- 241000218211 Maclura Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 244000233952 Polygonum bistorta Species 0.000 description 1
- 241000208476 Primulaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 240000000260 Typha latifolia Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 244000230030 foxtail bristlegrass Species 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000018984 snakeroot Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004325 uterine smooth muscle cell Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition, which comprises the following components in percentage by weight: 10-20 parts of barbed skullcap herb, 20-30 parts of desmodium, 10-20 parts of lithospermum and 40-60 parts of cudrania cochinchinensis. The composition provided by the invention has at least one of the following advantages that the composition is simple in components, the main components of the composition are common medicinal materials, such as barbat skullcap, desmodium, lithospermum and cudrania cochinchinensis, the source is wide, the material is convenient to obtain, and the price is low; the preparation method is simple and convenient, boiling or steaming is not needed, special instruments and equipment are not needed, and a user can prepare the medicine at home, and the medicine can be used after being prepared; the treatment effect is obvious, and no adverse side effect exists; fourthly, the cost is low, and the method is suitable for large-scale popularization.
Description
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a composition capable of treating hysteromyoma and application thereof.
Background
Uterine fibroids are the most common benign tumors in female reproductive organs, and are also one of the common tumors in the human body. Hysteromyoma is mainly formed by hyperplasia of uterine smooth muscle cells, and is commonly manifested by uterine bleeding, pain, abdominal mass, compression symptoms of adjacent organs, leukorrhagia, anemia, cardiac dysfunction and the like. Some patients have no symptoms, and the patients are usually found to have the hysteromyoma in gynecological general survey. It is commonly seen in 30-50 years old, and can be classified into intramural, subplasmic membrane, submucosal and intratough fibroid hysteromyoma according to the location of the myoma in the myoma wall. According to the traditional Chinese medicine, the hysteromyoma belongs to 'abdominal mass', the pathogenesis of the hysteromyoma is viscera dysfunction, visible pathogens such as blood stasis, phlegm stagnation, damp turbidity and the like are generated in succession, the uterus is accumulated, and the chronic disease is related to personal state and diet. During its development, the yin and blood are continuously consumed and the healthy qi is consumed. The patients mostly present with dull tongue, swollen tongue, tooth marks on the tongue edge, deep and thready pulse, and the symptoms of qi deficiency are usually accompanied by the symptoms of heavy abdomen, lassitude in loin and legs, dizziness and hypodynamia due to the excessive menstruation and the prolonged menstrual period. The primary symptoms of deficiency of the original qi are manifested as blood-borne lumps, sometimes with abdominal pain, and tongue with ecchymosis. In chronic diseases, qi deficiency involves yang deficiency, water-dampness is not transformed, and dampness is collected as phlegm, phlegm is sticky, and phlegm-blood stasis is combined.
At present, many traditional Chinese medicines are used for treating uterine fibroid, for example, the Chinese patent publication No. CN 102293991A discloses a secret recipe for treating uterine fibroid, which comprises 5-20% of dragon's blood, 5-20% of cattail pollen, 3-15% of amber, 5-20% of rhizoma alismatis, 5-20% of Chinese sage herb, 5-20% of cudrania cochinchinensis, 5-20% of oldenlandia diffusa, 5-20% of rhizoma sparganii, 5-20% of rhizoma zedoariae, 5-20% of leech, 5-20% of spora lygodii, 5-20% of pseudo-ginseng, 5-20% of red peony root, 5-20% of spina gleditsiae, 5-20% of lychee seed, 5-20% of chicken's gizzard-membrane, 5-20% of garden balsam; also disclosed in Chinese patent publication No. CN 103285172A is a Chinese medicinal composition for treating hysteromyoma and endometrial cancer, which comprises 13-30 parts of lithospermum, 15-30 parts of oldenlandia diffusa, 10-20 parts of selfheal, 10-20 parts of eclipta, 15-30 parts of gypsum rubrum and 10-20 parts of sculellaria barbata. However, the traditional Chinese medicine for treating hysteromyoma has more traditional Chinese medicines, is inconvenient to prepare and has higher cost, so that a traditional Chinese medicine composition for treating hysteromyoma, which has fewer medicines, is convenient to prepare and apply and has a remarkable treatment effect, is urgently needed.
Disclosure of Invention
Based on the above, the invention aims to provide the traditional Chinese medicine composition which is simple in preparation method, can be prepared by a patient at home, can be used at any time, and has an obvious curative effect.
The purpose of the invention is realized by the following technical scheme:
the invention provides a composition, which comprises the following components in percentage by weight: 10-20 parts of barbed skullcap herb, 20-30 parts of desmodium, 10-20 parts of lithospermum and 40-60 parts of cudrania cochinchinensis.
Wherein,
scutellaria barbata (school name: Scutellaria barbata D.Don) (plant material of Jiangsu province), which is called as follows: stringy exterior syndrome (Sichuan Chengdu), thin baikal skullcap root (Sichuan Puge), tooth-brush grass (Jiangsu Suzhou), Tianji grass (Jiangsu Yixing), Shuichu baikal skullcap root (Jiangsu Nanjing), and Han Xin grass (Guangzhou plant). The herba Scutellariae Barbatae has effects in clearing away heat and toxic materials, promoting blood circulation, dispelling blood stasis, relieving swelling and pain, and resisting cancer. Is cold in nature and sour in taste, and the whole herb contains various vitamins, trace elements, amino acids and other components. Has the effects of cooling blood, removing toxic substances, removing blood stasis, relieving pain, relieving swelling, clearing heat and promoting diuresis.
The herba Lysimachiae Christinae is fresh or dried whole plant of Lysimachia Hance of Primulaceae, Lysimachia christinae Hance, also named herba Desmodii Styracifolii, herba Lobeliae chinensis, herba Ardisiae Japonicae, and radix rehmanniae. Lysimachia christinae Hance is bitter, sour and slightly cold in taste. It enters liver, gallbladder, kidney and bladder meridians. Has the functions of clearing away heat and toxic material, promoting urination, removing urinary calculus, promoting blood circulation and dissipating blood stasis. Can be used for treating liver and gall calculus, cholecystitis, icterohepatitis, urinary calculus, edema, traumatic injury, venomous snake bite, and muscarine and drug poisoning; it is used externally to treat suppurative inflammation, burn and scald.
Lithospermum erythrorhizon Sieb. et Zucc. is a plant of the genus Lithospermum in the family Boraginaceae. The dried root is used as a medicine, has the effects of cooling blood, activating blood circulation, clearing heat, detoxicating and promoting eruption, and is used for treating diseases such as warm heat macula, damp-heat jaundice, hematemesis, maggot blood, hematuria, stranguria with turbid urine, bloody dysentery, heat accumulation constipation, burn, eczema, erysipelas and the like.
Breaking the stone: \ 33896, Zhi and jin Chan (synonyms) Cudrania tricuspidata root (Qian jin Fang), Chuan broken stone (preparation of herb) and Gossypium hirsutum root, shell removing, Huanglong shell removing, morning glory introducing stone, Jinwaistband, yellow snake root, mountain lichee and Qian Piao (source) Kudo et Masam, and root introducing medicine. [ PROPERTIES, WESTERN AND CHANNEL FENCH ] is slightly bitter and neutral. [ FUNCTIONS ] can relieve cough, resolve phlegm, dispel wind, promote diuresis, remove blood stasis, and relieve pain. Can be used for treating pulmonary tuberculosis, icterohepatitis, hepatosplenomegaly, gastric ulcer, duodenal ulcer, rheumatic lumbago, and skelalgia; it is used externally to treat fracture and traumatic injury.
In the application, the radix cudraniae is used as a monarch drug, the channels are penetrated, the stasis is broken, the sculellaria barbata is used as a ministerial drug, the radix cudraniae is used for assisting the radix cudraniae to detoxify and remove stasis, and improving and inhibiting tumors, and the lithospermum and the longhairy antenoron herb are used as guides for clearing heat and cooling blood, promoting diuresis, removing stasis, resisting bacteria and diminishing. The combination of the arnebia root and the desmodium helps the monarch drugs to remove blood stasis and eliminate mass, soften hardness and dissipate stagnation. The applicant combines the cudrania cochinchinensis, the sculellaria barbata, the lithospermum and the longhairy antenoron herb with each other, is used for inhibiting or treating the uterine fibroid, and has obvious effect and no toxic or side effect.
In one embodiment of the application, the composition comprises 13-19 parts of barbed skullcap herb, 22-26 parts of desmodium, 13-18 parts of lithospermum and 45-57 parts of cudrania cochinchinensis by weight ratio.
In one embodiment of the present application, the medicine comprises 16 parts of barbed skullcap herb, 25 parts of longhairy antenoron herb, 15 parts of sinkiang arnebia root and 52 parts of cudrania root by weight.
In one embodiment of the present application, the composition ingredients are mixed and ground to form a powder.
In one embodiment of the application, the composition comprises, by weight, 10-20 parts of barbed skullcap herb, 20-30 parts of longhairy antenoron herb, 10-20 parts of sinkiang arnebia root and 40-60 parts of cudrania cochinchinensis.
In one embodiment of the application, the composition comprises 13-19 parts of barbed skullcap herb, 22-26 parts of desmodium, 13-18 parts of lithospermum and 45-57 parts of cudrania cochinchinensis by weight ratio.
In one embodiment of the present application, the composition consists of 16 parts by weight of barbed skullcap herb, 25 parts by weight of longhairy antenoron herb, 15 parts by weight of sinkiang arnebia root and 52 parts by weight of cudrania cochinchinensis.
In another aspect, the present application provides a method for preparing the above composition, which comprises the following steps: mixing and grinding the components of the composition to form medicinal powder.
In one embodiment of the present application, the preparation method further comprises pulverizing the composition ingredients, sieving with an 80-mesh sieve, and mixing and grinding.
In one embodiment of the present application, the composition is mixed and ground to form a powder, which is taken directly with warm boiled water half an hour before meals twice a day.
In another aspect, the present application provides the use of the above composition, or the above prepared composition, for inhibiting and/or treating uterine fibroids.
In a further aspect, the present application provides the use of a composition as described above, or a composition prepared as described above, in the preparation of a medicament for inhibiting and/or inhibiting
Application in the medicine for treating hysteromyoma.
The invention has at least one of the following advantages:
the invention provides a composition, which has simple components, and the main components of the composition are common medicinal materials, namely sculellaria barbata, desmodium, lithospermum and cudrania cochinchinensis, and the composition has wide sources, convenient material acquisition and low price; the preparation method is simple and convenient, boiling or steaming is not needed, special instruments and equipment are not needed, and a user can prepare the medicine at home, and the medicine can be used after being prepared; the treatment effect is obvious, and no adverse side effect exists; fourthly, the cost is low, and the method is suitable for large-scale popularization.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1 preparation of the composition
The specific components and contents of the compositions in weight ratio are shown in the following table 1:
TABLE 1 specific Components and amounts of the compositions
| Examples of the invention | Herba Scutellariae Barbatae | Herba Lysimachiae Christinae | Lithospermum erythrorhizon | Piercing stone |
| 1 | 10 | 27 | 13 | 40 |
| 2 | 18 | 30 | 15 | 50 |
| 3 | 13 | 20 | 16 | 60 |
| 4 | 19 | 25 | 10 | 45 |
| 5 | 20 | 29 | 18 | 48 |
| 6 | 12 | 22 | 20 | 43 |
| 7 | 15 | 26 | 17 | 57 |
| 8 | 16 | 25 | 15 | 52 |
The compositions of the above examples were prepared as follows: processing the above materials, baking, pulverizing, and sieving with 80 mesh sieve; then weighing the contents of the components according to the weight ratio, mixing and grinding to form the medicinal powder.
EXAMPLE 2 clinical use of the composition
The compound prepared in the example 8 is used as an example to treat patients with hysteromyoma, and the treatment time is 3 months as a treatment course and 3 treatment courses. And carrying out later-stage tracking observation on the patient, and recording the feeling and effect of the patient after use.
Patient symptoms: 128 patients with hysteromyoma, age 45-56 years, course of disease 1 month to 8 years, hysteromyoma 2.2cm × 2.5cm × 2.7cm to 12.3cm × 10.2cm × 11.8cm, are divided into two groups at random, one group is control group, and the other group is treatment group.
The treatment method comprises the following steps:
treatment groups: the powder of example 8 is weighed to about 7g (the powder can also be packaged by 7g per bag in advance), half an hour before meal, and taken with warm boiled water, once a day in the morning and at night.
Control group: 30 parts of lithospermum, 30 parts of oldenlandia diffusa, 12 parts of selfheal, 12 parts of eclipta, 30 parts of gypsum rubrum and 20 parts of sculellaria barbata are decocted by a conventional method until the crude drug content is 0.25g/ml, 1 dose is taken every day, and 10ml is taken as 1 dose.
Treatment criteria were:
after the treatment is finished, B ultrasonic examination is carried out to check the hysteromyoma condition:
the method has the following advantages: the hysteromyoma completely disappears or shrinks more than 1/2;
remarkably: uterine fibroids shrink below 1/2;
and (4) invalidation: uterine fibroids were unchanged, even enlarged.
② the difference of menstrual flow before and after the treatment:
the method has the following advantages: menopause or a reduction in menstrual flow of greater than about 1/2, or a return in menses to normal;
remarkably: a reduction in menstrual flow of less than about 1/2, or a significant reduction in menstrual duration, or a significant prolongation of the menstrual cycle;
and (4) invalidation: there was no significant change in menses.
After the treatment, the treatment results of the uterine fibroid are shown in table 2; the results of the treatment on menstrual flow are shown in table 3.
TABLE 2 treatment results for uterine fibroids size in patients
| Is effective | Is remarkable in that | Invalidation | Total effective rate | |
| Treatment group | 31 | 28 | 5 | 92.2％ |
| Control group | 27 | 24 | 13 | 79.7％ |
TABLE 3 treatment results for menstrual flow in patients
| Is effective | Is remarkable in that | Invalidation | Total effective rate | |
| Treatment group | 37 | 24 | 3 | 95.3％ |
| Control group | 28 | 28 | 8 | 87.5％ |
From the above experimental results, compared with the traditional Chinese medicine composition-control group in the prior art, the traditional Chinese medicine composition-treatment group of the application has the advantages that the total effective rate is obviously higher than that of the control group, and patients who completely eliminate hysteromyoma after 3 treatment courses are also obviously higher than that of the control group, so that the effect is very obvious; moreover, the traditional Chinese medicine composition can also obviously reduce the menstrual flow of patients. The composition provided in the embodiment of the application can inhibit or treat the hysteromyoma, and the patient is tracked and observed, so that the patient has no relapse or adverse reaction.
In summary, the traditional Chinese medicine composition has the effects of removing blood stasis, stopping bleeding, stopping menstruation and eliminating tumor, and can effectively treat hysteromyoma and reduce the menstruation of patients to recover to normal. The composition has few flavors, is convenient to prepare, does not need operation processes such as cooking and the like, only needs to process and process the components of the composition, dry the components, grind the components, sieve the components, weigh the components according to the proportion, mix and grind the components, can be prepared at any time, is simple and quick, is easy to popularize, and has wide application prospect.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and the like that are within the spirit and principle of the present invention are included in the present invention.
Claims (10)
1. The composition is characterized by comprising the following components in parts by weight:
10-20 parts of barbed skullcap herb, 20-30 parts of desmodium, 10-20 parts of lithospermum and 40-60 parts of cudrania cochinchinensis.
2. The composition as claimed in claim 1, which comprises 13-19 parts by weight of barbed skullcap herb, 22-26 parts by weight of longhairy antenoron herb, 13-18 parts by weight of sinkiang arnebia root and 45-57 parts by weight of cudrania cochinchinensis.
3. The composition according to claim 1, comprising 16 parts of barbed skullcap herb, 25 parts of longhairy antenoron herb, 15 parts of sinkiang arnebia root and 52 parts of cudrania cochinchinensis.
4. The composition of claim 1, wherein the composition ingredients are mixed and milled to form a powder.
5. The composition of claim 1, wherein the composition comprises, by weight, 10-20 parts of barbed skullcap herb, 20-30 parts of longhairy antenoron herb, 10-20 parts of sinkiang arnebia root, and 40-60 parts of cudrania cochinchinensis.
6. The composition of claim 1, wherein the composition comprises 13-19 parts by weight of barbed skullcap herb, 22-26 parts by weight of longhairy antenoron herb, 13-18 parts by weight of sinkiang arnebia root and 45-57 parts by weight of cudrania cochinchinensis.
7. The composition of claim 1, wherein the composition comprises 16 parts by weight of sculellaria barbata, 25 parts by weight of lysimachia christinae hance, 15 parts by weight of lithospermum erythrorhizon and 52 parts by weight of radix cudraniae.
8. A process for the preparation of a composition according to any one of claims 1 to 7, characterized in that it comprises the following steps: mixing and grinding the components of the composition to form medicinal powder.
9. The method of claim 8, further comprising separately pulverizing the composition ingredients and sieving the pulverized composition ingredients through an 80 mesh sieve before mixing the composition ingredients.
10. Use of the composition of any one of claims 1-7, or the composition prepared according to claim 8 or 9, for the treatment of, or for the manufacture of a medicament for the treatment of, uterine fibroids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010574137.3A CN111643547A (en) | 2020-06-22 | 2020-06-22 | Composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010574137.3A CN111643547A (en) | 2020-06-22 | 2020-06-22 | Composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111643547A true CN111643547A (en) | 2020-09-11 |
Family
ID=72343084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010574137.3A Pending CN111643547A (en) | 2020-06-22 | 2020-06-22 | Composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111643547A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285172A (en) * | 2013-05-24 | 2013-09-11 | 上海市中医医院 | Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof |
| CN103385953A (en) * | 2013-07-18 | 2013-11-13 | 上海中医药大学附属岳阳中西医结合医院 | A traditional Chinese medicine composition for the treatment of menopausal uterine fibroids and applications thereof |
-
2020
- 2020-06-22 CN CN202010574137.3A patent/CN111643547A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285172A (en) * | 2013-05-24 | 2013-09-11 | 上海市中医医院 | Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof |
| CN103385953A (en) * | 2013-07-18 | 2013-11-13 | 上海中医药大学附属岳阳中西医结合医院 | A traditional Chinese medicine composition for the treatment of menopausal uterine fibroids and applications thereof |
Non-Patent Citations (2)
| Title |
|---|
| 何清湖等: "《妇科良方大全》", 31 October 2006, 山西科学技术出版社 * |
| 黄夑才: "《常用中草药识别与应用》", 30 September 1999, 化学工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN105434648A (en) | Traditional Chinese medicine composition for treating acute mastitis and preparation method thereof | |
| CN101569739B (en) | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof | |
| CN105533253A (en) | Feed additive for treating quail disease | |
| CN102078569A (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN103920034A (en) | Traditional Chinese medicine composition for alleviating side effects of chemotherapy of cancer patient and preparation method traditional Chinese medicine composition | |
| CN104225486A (en) | Traditional Chinese medicine for treating chronic cholecystitis | |
| CN111643547A (en) | Composition and preparation method thereof | |
| CN111973720A (en) | A Chinese medicinal composition for treating mastitis and hyperplasia of mammary glands, and its preparation method | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN111467441A (en) | Pharmaceutical composition for preventing and treating gout, preparation and application | |
| CN105560687A (en) | Traditional Chinese medicine compound external coating liquid for treating skin ulcers and preparation method and application thereof | |
| CN104623414A (en) | Traditional Chinese medicine composition for treating nutritional obesity | |
| CN104257986A (en) | Traditional Chinese medicine for treating nephritis | |
| CN114632131B (en) | Traditional Chinese medicine composition for softening hardness and resolving hard mass, preparation method and application | |
| CN101129822B (en) | Orally taken traditional Chinese medicine composition for treating bronchiolectasis | |
| CN106728369A (en) | One group of Chinese medicine for effectively treating leukaemia | |
| CN1327866C (en) | Black powder for treating burn and empyrosis and its preparing process | |
| CN105213644A (en) | A kind of Chinese medicine preparation for the treatment of acute mastitis and preparation method thereof | |
| CN105012789A (en) | Composition for treating cervical cancer and preparation method thereof | |
| CN113876909A (en) | Composition for preventing prostatic hyperplasia and preparation method thereof | |
| CN101028373B (en) | Decoction for treating gravida cold and its production | |
| CN116870054A (en) | Traditional Chinese medicine composition, application, gel and preparation method of gel | |
| CN113786451A (en) | A Chinese medicinal composition for treating gynecological tumor and preparation method thereof | |
| CN116370524A (en) | Traditional Chinese medicine composition for treating prostate and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200911 |
|
| RJ01 | Rejection of invention patent application after publication |